2023年1月10日

推動市場增長的主要原因之一是全球範圍內由微生物生態失調引起的慢性生活方式疾病和感染的日益流行。此外，更容易受到這些疾病影響的老齡化人口正在推動市場擴張。市場的擴張也可以歸因於人們越來越重視為人類微生物組創造更有效的藥物。為了有效地治療各種胃腸道疾病，人類腸道微生物群正在以精確的組合進行培養。與此同時，冠狀病毒(COVID-19)大流行的開始也推動了市場擴張。為了評估疾病的嚴重程度，並製定必要的治療方法和疫苗，研究人員正在深入研究肺部微生物群。根據應用，全球人類微生物組市場被細分為:治療學診斷在預測期內主導市場，並將在預測期內繼續主導市場。在治療COVID-19、IBD、艱難梭菌感染、克羅恩病和糖尿病方麵，微生物組療法有廣泛的用途。由於研究機構正在加大研究力度，以確定人類微生物組的進一步藥用用途，預計這一增長將會加速。例如，蘇黎世大學在2020年對COVID-19患者的微生物組進行了檢測，以確定未來可能采取的治療和預防措施(MICRO-COV)。 Positive findings from these research investigations will widen the segment under study's options for expansion. Human gastrointestinal microbiome research can contribute significantly to clinical and therapeutic development if it moves toward mechanistic studies, according to an article in the Frontiers in Microbiology Journal titled "Key Technologies for Progressing Discovery of Microbiome-Based Medicines" that was published in June 2021. Additionally, it was suggested that establishing causal relationships between the microbiome and disease is necessary for the development of more effective and targeted treatments. Future development will depend on strong collaborations between cutting-edge sequencing techniques, computational analyses, and experimental assays. The market expands as a result of these research. Excerpts from ‘By Region Segmentation’ Based on region, the global human microbiome market has been segmented into: North America Rest Of The World Due to the increasing prevalence of autoimmune disorders and diseases linked to a sedentary lifestyle in these areas, North America presently controls the majority of the global market for the human microbiome. The extremely profitable growth can also be ascribed to a solid medication pipeline. For instance, in 2019, the phase-III of clinical trials for Seres Therapeutics' stool-derived therapy for recurrent Clostridium difficile infection was successful. To take advantage of the communities of microorganisms that live inside human bodies, Stanford ChEM-H and the Department of Bioengineering together created the Stanford Microbiome Therapies Initiative (MITI) in August 2019. The National Institutes of Health (NIH) support the microbiome initiative, with 21 out of 27 NIH institutes supporting and funding this field through extramural projects, according to an article in BioMed Central Journal, 2019. Additionally, the Canadian government committed an expenditure of USD 18 million in microbiome research in 2019. With the help of this investment, seven research teams from all around the nation may be able to better understand how the microbiome affects conditions including diabetes, inflammatory bowel disease in children, foetal malnutrition, and childhood asthma. As a result, the human microbiome market in North America has become one of the leading markets and is expanding at a healthy rate because to these research activities and increased government support. Excerpts from ‘Competitive Landscape’